Meyer T, Funke A, Münch C, et al. - In this registry study, researchers analyzed the real world experience in the use of a standardised oromucosal spray containing tetrahydrocannabinol:cannabidiol (THC:CBD) for symptomatic treatment of spasticity related to amyotrophic lateral sclerosis (ALS). A retrospective mono-centric cohort study has been conducted in 32 patients who meet the following criteria: ALS diagnosis, ALS-related spasticity, treatment with THC:CBD. According to findings, THC:CBD is used in a wide dose range indicating that the drug was applied based on the needs and preferences of individual patients. In contrast to patients with mild spasticity, moderate to severe spasticity was linked to a high amount of daily THC:CBD actuations and stronger recommendation rate (NPS). Overall, there was high satisfaction with treatment (TSQM-9). The findings indicate that in the spectrum of symptomatic therapy in ALS, THC:CBD can be a useful complement. However, prospective studies and head-to-head comparisons with other spasticity medicines are of concern in further exploring the efficacy of THC:CBD in spasticity management and other symptoms associated with ALS.